BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Cell

• Publication date

  2011-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cell.2011.08.017PMID 21889194PMCID PMC3187920
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Brd4 Extraterminal Domain Confers Transcription Activation Independent of pTEFb by Recruiting Multiple Proteins, Including NSD3

  2011cited by this paper
• An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance.

  2011cited by this paper
• RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

  2011cited by this paper
• Initial genome sequencing and analysis of multiple myeloma

  2011cited by this paper
• Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma

  2011cited by this paper
• c-Myc regulates transcriptional pause release.

  2010cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• Small-molecule inhibitors of c-Myc transcriptional factor suppress proliferation and induce apoptosis of promyelocytic leukemia cell via cell cycle arrest.

  2010cited by this paper
• Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity

  2010influential reference
• Inhibition of Myc effectively targets KRAS mutation-positive lung cancer expressing high levels of Myc.

  2010cited by this paper
• Suppression of inflammation by a synthetic histone mimic

  2010influential reference
• The landscape of somatic copy-number alteration across human cancers

  2010influential reference
• The art of the chemical probe.

  2010cited by this paper
• Evaluation of the 8q24 prostate cancer risk locus and MYC expression.

  2009cited by this paper
• Nuclear topography of the 1q21 genomic region and Mcl-1 protein levels associated with pathophysiology of multiple myeloma.

  2009cited by this paper
• MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities

  2009cited by this paper
• Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides.

  2009cited by this paper
• Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc.

  2009cited by this paper
• Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription.

  2009cited by this paper
• The 8q24 cancer risk variant rs6983267 demonstrates long-range interaction with MYC in colorectal cancer

  2009cited by this paper
• MYC, microRNAs and glutamine addiction in cancers

  2009cited by this paper
• IRF4 addiction in multiple myeloma

  2008cited by this paper
• AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

  2008influential reference
• An extended transcriptional network for pluripotency of embryonic stem cells.

  2008cited by this paper
• Characterization of MYC translocations in multiple myeloma cell lines.

  2008influential reference
• Adjusting batch effects in microarray expression data using empirical Bayes methods.

  2007cited by this paper
• Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation

  2007cited by this paper
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

  2007influential reference
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

  2007cited by this paper
• Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription

  2007cited by this paper
• The Bcl-2 Family Protein Inhibitor, ABT-737, Has Substantial Antimyeloma Activity and Shows Synergistic Effect with Dexamethasone and Melphalan

  2007cited by this paper
• Integrative genomic approaches identify IKBKE as a breast cancer oncogene.

  2007cited by this paper
• Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.

  2006cited by this paper
• A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen.

  2006cited by this paper
• Statistical practice in high-throughput screening data analysis

  2006cited by this paper
• Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification

  2006cited by this paper
• Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma

  2005influential reference
• Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line

  2005cited by this paper
• An inhibitor of Bcl-2 family proteins induces regression of solid tumours

  2005cited by this paper
• limma: Linear Models for Microarray Data

  2005cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper
• Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

  2004cited by this paper
• Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.

  2004cited by this paper
• Summaries of Affymetrix GeneChip probe level data.

  2003cited by this paper
• A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

  2003cited by this paper
• An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo

  2003cited by this paper
• X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors.

  2003cited by this paper
• Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

  2003cited by this paper
• MYC recruits the TIP60 histone acetyltransferase complex to chromatin

  2003cited by this paper
• Stimulation of c‐MYC transcriptional activity and acetylation by recruitment of the cofactor CBP

  2003cited by this paper
• E2F1 and c-Myc in Cell Growth and Death

  2003cited by this paper
• An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets

  2003cited by this paper
• Transcription factors as targets for cancer therapy

  2002cited by this paper
• Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC

  2002cited by this paper
• Signaling network model of chromatin.

  2002cited by this paper
• Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis.

  2002cited by this paper
• Transcription: Sibling rivalry in the E2F family

  2002cited by this paper
• Molecular sequelae of proteasome inhibition in human multiple myeloma cells

  2002influential reference
• A molecular compendium of genes expressed in multiple myeloma.

  2002influential reference
• The transcriptional program of a human B cell line in response to Myc.

  2001cited by this paper
• Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma.

  2000cited by this paper
• Structure and ligand of a histone acetyltransferase bromodomain

  1999cited by this paper
• Expression of Bcl-2 family of proteins in fresh myeloma cells

  1998cited by this paper
• Design and properties of a Myc derivative that efficiently homodimerizes

  1998cited by this paper
• Oncogenic activity of the c-Myc protein requires dimerization with Max.

  1993influential reference
• The bromodomain: a conserved sequence found in human, Drosophila and yeast proteins.

  1992cited by this paper
• Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc.

  1991cited by this paper
• Glucocorticoid effects on myeloma cells in culture: correlation of growth inhibition with induction of glucocorticoid receptor messenger RNA.

  1990cited by this paper
• Altered expression of growth-regulated protooncogenes in human malignant plasma cells.

  1989cited by this paper
• The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells

  1988influential reference
• Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development.

  1986cited by this paper
• Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes.

  1984cited by this paper
• Transcriptional activation of immunoglobulin α heavy-chain genes by translocation of the c-myc oncogene

  1983cited by this paper

• Epigenetic suppression of synovial inflammation and osteoclast differentiation in rheumatoid arthritis by I-BET762

  2026cites this paper
• Targeting BRD4—A Promising Therapeutic Option for Glioblastoma?

  2026cites this paper
• Happening in the Prostate Tumor Microenvironment: Ion Channels and Extrachromosomal DNA Driving Phenotypic Plasticity.

  2026cites this paper
• The polygenic, omnigenic and stratagenic models of complex disease risk

  2026cites this paper
• The leading role of MYC in DNA damage response: exploring opportunities for therapeutic inhibition

  2026cites this paper
• CRISPR/Cas13a-Engineered RNA-Based Fluorogenic Biosensor for Label-Free Quantification of RNA in Colorectal Tissues.

  2026cites this paper
• BRD4 represses developmental and neuronal genes through interactions with polycomb complexes

  2026cites this paper
• Targeting extrachromosomal DNA in human cancers.

  2026cites this paper
• Alternative Strategies of Reducing MYC Expression for the Treatment of Cancers.

  2026cites this paper
• Combined inhibition of FACT and BET disrupts transcription to suppress tumor growth in mouse models of diffuse midline glioma.

  2026cites this paper
• BRD4 orchestrates the metabolic-epigenetic regulation of GM-CSF expression and secretion to drive PD-L1⁺ macrophage-mediated immune evasion in triple-negative breast cancer

  2026cites this paper
• Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition.

  2026cites this paper
• Establishment of novel stable human sinonasal NUT carcinoma cell lines.

  2026cites this paper
• MYC at the tumor–immune interface: mechanisms of immune escape and immunotherapy resistance

  2026cites this paper
• Fibrillarin: bridging ribosome biogenesis and apoptosis in cellular stress and disease

  2026cites this paper
• The research landscape and future of targeting super-enhancers for cancer therapy: a bibliometric analysis

  2026cites this paper
• Development of Dihydroquinoxalinone-Based Dual CDK6/BET Inhibitors for Triple-Negative Breast Cancer Therapy.

  2026cites this paper
• MBD3 increased expression by BRD4 and facilitated castration-resistant prostate cancer cell proliferation by inhibiting PTEN.

  2026cites this paper
• Machine learning-based comprehensive analysis of m6A RNA methylation regulators in colorectal cancer: implications for prognosis, immune microenvironment, and immunotherapy response

  2026cites this paper
• Disrupting CDK9 activity suppresses triple-negative breast cancer and is enhanced by EGFR Inhibition

  2026cites this paper
• Dual targeting of AMRC12 and Malassezia globosa disrupts MYC liquid condensates-driven nuclear pore complex biogenesis in neuroblastoma

  2026cites this paper
• Role and Molecular Mechanisms of Aerobic Glycolysis in Gastrointestinal Tumors

  2026cites this paper
• Dual Target E3 Ligase Ligands: A New Way to Overcome Drug Resistance

  2026cites this paper
• Epigenetic profiling reveals key super-enhancer networks driving oncogenesis in HPV-positive HNSCC

  2025cites this paper
• Pathway‐level mutational signatures predict breast cancer outcomes and reveal therapeutic targets

  2025cites this paper
• The Effect of Myc Inhibition Combined with the Synergistic Effect of Photothermal, Photodynamic and Radiotherapy in Tumor Treatment

  2025cites this paper
• Targeting BRD4 in cancer therapy: From inhibitors and degraders to novel combination strategies and resistance mechanisms.

  2025cites this paper
• Bromodomain containing protein 4 (BRD4) and cancer therapy: A glimpse at dual-target drug development.

  2025cites this paper
• HNF1A is a novel BRD4 target and critical for BET-inhibitor response in pancreatic ductal adenocarcinoma

  2025cites this paper
• TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial.

  2025cites this paper
• Cell-based high-throughput screening using a target–NanoLuc fusion construct to identify molecular glue degraders of c-Myc oncoprotein

  2025cites this paper
• NFE2 and PF4 as biomarkers for BET inhibition-induced thrombocytopenia in preclinical and clinical studies

  2025cites this paper
• BRD2 Upregulation as a Pan-Cancer Adaptive Resistance Mechanism to BET Inhibition

  2025cites this paper
• Unc-51 Like Kinase 3 (ULK3) is essential for autophagy and cell survival in multiple myeloma

  2025cites this paper
• Interpretable bioinformatics approaches for pheochromocytoma bioactivity and protein interaction analysis

  2025cites this paper
• Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities

  2025cites this paper
• BRD2 bridges TFIID and histone acetylation to promote transcriptional initiation

  2025cites this paper
• The chordoid glioma-associated PRKCA D463H mutation is a kinase inactive, gain-of-function allele that induces chondrosarcoma in mice

  2025cites this paper
• SETD6 mediates selective interaction and genomic occupancy of BRD4 and MITF in melanoma cells

  2025cites this paper
• The ESCRT protein CHMP5 promotes T cell leukemia by enabling BRD4-p300-dependent transcription

  2025cites this paper
• Targeting c-MYC has a Key Role in Hepatocellular Carcinoma Therapy.

  2025cites this paper
• Current progress and future perspective of super-enhancers: a viable and effective bridge between the transcriptional apparatus and disease

  2025cites this paper
• Jq1 Induces Apoptosis of Ovarian and Endometrial Endometrioid Carcinoma Cells by Downregulating C-Myc Sex

  2025cites this paper
• The penetrant chordoid glioma PRKCA mutation is an oncogenic gain-of-function kinase inactivation eliciting early onset chondrosarcoma in mice

  2025cites this paper
• Reprogramming of Cellular Plasticity via ETS and MYC Core-regulatory Circuits During Response to MAPK Inhibition in BRAF-mutant Colorectal Cancer

  2025cites this paper
• A circular RNA overcomes acquired resistance to BET inhibitors by antagonizing IGF2BP2-mediated c-MYC translation in TNBC

  2025cites this paper
• Overcoming BET‐inhibitor JQ1 resistance in aggressive non‐small cell lung cancer by inducing ferroptosis via inhibition of the BRD2–FTH1 axis

  2025cites this paper
• Multi-omics analysis revealed the addiction to glutamine and susceptibility to de novo lipogenesis of endometrial neoplasm

  2025cites this paper
• Deep learning model enables the discovery of a novel BET inhibitor YD-851.

  2025cites this paper
• SUCLG1 deficiency-induced histone succinylation impairs oncogene expression in acute myeloid leukemia.

  2025cites this paper
• The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active

  2025cites this paper
• C‐Myc Overexpression in Adolescent and Young Adult Breast Cancer: Distinct From Older Adults With Relevantly Expressed Cholecystokinin B Receptor

  2025cites this paper
• Discovery of 2-(Pyrazol-4-yl)-quinazolin-4(3H)-one Derivatives as Subnanomolar BRD4 BD2 Inhibitors with High Selectivity via a Bioisosterism Approach.

  2025cites this paper
• Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma

  2025cites this paper
• Chromatin Regulatory Targets for Anticancer Therapeutics.

  2025cites this paper
• Recent advances and strategies in BET bromodomain inhibition for drug discovery.

  2025cites this paper
• BET bromodomain inhibition reverses CDK4/6 inhibitor resistance in estrogen receptor-positive breast cancer via induction of miR-34a-5p.

  2025cites this paper
• The Role of MYC in Tumor Immune Microenvironment Regulation: Insights and Future Directions.

  2025cites this paper
• Targeting CLEC4E in immunosuppressive tumour‐associated macrophages via BET inhibition

  2025cites this paper
• Discovery of Novel PI3K/BRD4 Dual Inhibitors for Esophageal Cancer: Rational Design, Optimization, and Senescence-Inducing Mechanisms.

  2025cites this paper
• Peptide molecular glues select between BET paralogues by exploiting allosteric sites and conformational dynamics

  2025cites this paper
• CENP-F promotes HCC cell proliferation mediated by super enhancer reader BRD4

  2025cites this paper
• Synergistic Effects of BET Inhibitors and Ferroptosis Inducers via Targeted Inhibition of the BRD4/c-Myc/NRF2 Pathway in AML.

  2025cites this paper
• MYCN as an oncogene in pediatric brain tumors

  2025cites this paper
• Attenuation of c-Myc expression in breast cancer by hesperidin-mediated stabilization of its promoter proximal G quadruplex region.

  2025cites this paper
• Interplay between BET Proteins and the Pre-Replication Complex Unveils Therapeutic Vulnerabilities in Cancer

  2025cites this paper
• Epigenetic Rewiring of Protein Kinase Signalling in T-Cell Acute Lymphoblastic Leukaemia

  2025cites this paper
• Targeting Myc through BET-PROTAC elicits potent anti-lymphoma activity in diffuse large B cell lymphoma

  2025cites this paper
• Deciphering the dynamics of histone acetylation and chromatin remodeling in multiple myeloma: a tale beyond the tails.

  2025cites this paper
• Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy

  2025cites this paper
• Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains.

  2025cites this paper
• A triple-mode strategy on JQ1-loaded nanoplatform for superior antitumor therapy in pancreatic cancer

  2025cites this paper
• Development and comparison of single FLT3-inhibitors to dual FLT3/TAF1-inhibitors as an anti-leukemic approach

  2025cites this paper
• MYC ecDNA promotes intratumour heterogeneity and plasticity in PDAC

  2025cites this paper
• Discovery of Bi-magnolignan as a novel BRD4 inhibitor inducing apoptosis and DNA damage for cancer therapy.

  2025cites this paper
• Macrocyclic dihydropyridine analogs as pan-BET BD2-preferred inhibitors.

  2025cites this paper
• Discovery of Highly Potent BET Inhibitors based on a Tractable Tricyclic Scaffold

  2025cites this paper
• Targeting MYC with protein drugs.

  2025cites this paper
• scBiopsy-seq: a platform for temporal single-cell RNA-seq analysis

  2025cites this paper
• Modified screening of MYC promotor region elements using the CRISPR library in ovarian cancer

  2025cites this paper
• Is Enhancer Function Driven by Protein–Protein Interactions? From Bacteria to Leukemia

  2025cites this paper
• Harnessing the SPOP E3 Ubiquitin Ligase via a Bridged Proteolysis Targeting Chimera (PROTAC) Strategy for Targeted Protein Degradation.

  2025cites this paper
• Systemic genome-epigenome analysis captures a lineage-specific super-enhancer for MYB in gastrointestinal adenocarcinoma

  2025cites this paper
• Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse

  2025cites this paper
• Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.

  2025cites this paper
• ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27

  2025cites this paper
• Bromodomain and Extra-Terminal Family Proteins BRD2, BRD3, and BRD4 Contribute to H19-Dependent Transcriptional Regulation of Cell Adhesion Molecules, Modulating Metastatic Dissemination Program in Prostate Cancer

  2025cites this paper
• CRISPR/Cas9-directed epigenetic editing in colorectal cancer.

  2025cites this paper
• Resistance to the KRASG12D Inhibitor MRTX1133 is Associated with Increased Sensitivity to BET Inhibition

  2025cites this paper
• Development of a potent BET inhibitor for the treatment of renal fibrosis.

  2025cites this paper
• Targeting protein disorder: the next hurdle in drug discovery

  2025cites this paper
• BET bromodomain inhibitors attenuate transcription of a subset of IL-1-induced NF-κB targets that promote inflammation in β-cells

  2025cites this paper
• Gαq-Stimulated Gene Expression Is Insensitive to Bromo Extra Terminal Domain Inhibitors in HEK 293 Cells

  2025cites this paper
• Functional Roles and Mechanistic Insights of YEATS Domain Proteins in Digestive System Tumors

  2025cites this paper
• Inhibition of tumor growth using A conjugated nanobody that specifically targets c-MYC

  2025cites this paper
• P300-dependent acetylation of the FOXQ1 complex activates super-enhancers to promote colorectal cancer proliferation and metastasis

  2025cites this paper
• Multiple functions of BRD4 in maintaining genomic stability in cancers.

  2025cites this paper
• Multi-omics based and AI-driven drug repositioning for epigenetic therapy in female malignancies

  2025cites this paper
• New frontiers in prostate cancer treatment from systemic therapy to targeted therapy

  2025cites this paper
• PROTAC-loaded nanocapsules degrading BRD4 for radio-chemotherapy sensitization in glioblastoma

  2025cites this paper